Abstract
Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antibodies, Viral / blood
-
Antiviral Agents / therapeutic use*
-
Cytomegalovirus / immunology
-
Cytomegalovirus Infections / immunology
-
Cytomegalovirus Infections / therapy
-
Fatigue Syndrome, Chronic / immunology
-
Fatigue Syndrome, Chronic / therapy*
-
Fatigue Syndrome, Chronic / virology
-
Female
-
Herpesviridae Infections / immunology
-
Herpesviridae Infections / therapy
-
Herpesvirus 4, Human / immunology
-
Herpesvirus 6, Human / immunology
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Placebos
-
Transfer Factor / therapeutic use*
Substances
-
Antibodies, Viral
-
Antiviral Agents
-
Placebos
-
Transfer Factor